RxDoctor Payments Data

Augustine Joseph, MD

Neurology · Orlando, FLNPI 1750360459

Payments from drug & device makers

$23,635in general payments, 2019–2025

Across 1,397 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Acadia Pharmaceuticals Inc$2K
  • Biogen$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • plus $14K from 53 others

What the payments were for

  • Speaking & faculty fees$150%
  • Food & beverage$23,579100%
  • Education$420%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)160$2,424
Acadia Pharmaceuticals Inc104$1,717
Biogen90$1,488
Teva Pharmaceuticals USA, Inc.99$1,411
Lilly USA, LLC66$1,325
Amgen68$1,159
MDD US Operations, LLC80$1,099
UCB, Inc.59$1,068
Eisai Inc.55$933
SK Life Science, Inc.36$770
Tanabe Pharma America, Inc.27$676
Novartis58$660
Neurocrine Biosciences, Inc.29$628
Pfizer46$596
Argenx US, Inc.43$568
Sanofi27$566
Bristol Myers Squibb33$544
EMD Serono, Inc.19$390
Genentech USA, Inc.21$384
AstraZeneca20$366
Supernus Pharmaceuticals, Inc.27$365
Biohaven Pharmaceutical Holding Company Ltd.21$361
Mallinckrodt Hospital Products Inc.14$304
Johnson & Johnson13$303
Adamas Pharmaceuticals, Inc.17$298
Catalyst Pharmaceuticals, Inc.17$288
Lundbeck LLC13$272
Jazz Pharmaceuticals Inc.12$268
Biohaven Pharmaceuticals, Inc.13$263
Takeda Pharmaceuticals U.S.A., Inc.9$191
Amneal Pharmaceuticals LLC9$165
Vanda Pharmaceuticals Inc.8$154
Sumitomo Pharma America, Inc.10$147
Otsuka America Pharmaceutical, Inc.7$146
Boston Scientific6$143
Acorda Therapeutics, Inc6$128
CSL Behring6$118
Scilex Pharmaceuticals Inc.6$110
Corium, LLC5$90
Neurelis, Inc.4$76
Grifols USA, LLC4$68
Banner Life Sciences, LLC3$66
Harmony Biosciences LLC3$65
ANI Pharmaceuticals, Inc.2$52
Bausch Health US, LLC2$46
TG Therapeutics, Inc.2$43
E.r. Squibb & Sons, L.L.C.2$42
Mallinckrodt Enterprises LLC2$40
Avion Pharmaceuticals2$37
Assertio Therapeutics, Inc.2$36
Avanir Pharmaceuticals, Inc.2$33
Cycle Pharmaceuticals Inc1$26
Upsher-smith Laboratories LLC1$23
Livanova USA, Inc.1$19
Azurity Pharmaceuticals, Inc.1$19
Merz Pharmaceuticals, LLC1$17
Life Molecular Imaging Ltd1$16
Currax Pharmaceuticals LLC1$15
Metacel Pharmaceuticals LLC1$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,635 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$108,319
Medicare patients
205
Services billed
7,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ApokynApomorphine Hcl17$361,702
NuplazidPimavanserin Tartrate49$228,750
PonvoryPonesimod13$122,616
TecfideraDimethyl Fumarate12$112,772
Nurtec OdtRimegepant Sulfate45$76,377
AustedoDeutetrabenazine11$75,996
XcopriCenobamate70$75,824
BotoxOnabotulinumtoxina47$59,183
Aimovig AutoinjectorErenumab-Aooe39$44,535
GocovriAmantadine Hcl12$41,106
FycompaPerampanel30$37,244
Emgality PenGalcanezumab-Gnlm26$27,147
XadagoSafinamide Mesylate13$22,635
QuliptaAtogepant16$17,686
UbrelvyUbrogepant12$17,655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$1,717$228,75049 claims
Johnson & JohnsonPonvory$303$122,61613 claims
BiogenTecfidera$1,488$112,77212 claims
AbbVieBotox, Qulipta, Ubrelvy$2,424$94,52375 claims
PfizerNurtec Odt$596$76,37745 claims
Teva Pharmaceuticals USA, Inc.Austedo$1,411$75,99611 claims
SK Life Science, Inc.Xcopri$770$75,82470 claims
MDD US Operations, LLCGocovri$1,099$41,10612 claims
Eisai Inc.Fycompa$933$37,24430 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$165$14,70448 claims
Upsher-smith Laboratories LLCTopiramate$23$2,277144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,434 neurology providers in Florida.

Other neurology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →